Impute.me: an open source, non-profit tool for using data from DTC genetic testing to calculate and interpret polygenic risk scores.

Lasse Folkersen[1]†, Oliver Pain[2], Andres Ingasson[1], Thomas Werge[1]‡, Cathryn M. Lewis[2,3]‡, Jehannine Austin[4]‡

†Corresponding author

‡Equal contribution

1 Institute of Biological Psychiatry, Mental Health Centre Sankt Hans, Copenhagen, Denmark

2 Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London UK.

3 Department of Medical & Molecular Genetics, Faculty of Life Sciences & Medicine, King's College London, London, UK

4 Departments of Psychiatry and Medical Genetics, University of British Columbia, Vancouver, Canada

* Correspondence:
Lasse Folkersen lasse.folkersen@regionh.dk

Keywords: Genetics, Polygenic Risk Scores, Direct-to-consumer, Personal genomes, Risk Prediction. (Min.5-Max. 8)

Abstract

21 To date, interpretation of genomic information has focused on single variants conferring disease risk,
22 but most disorders of major public concern have a polygenic architecture. Polygenic risk scores
23 (PRS) give a single measure of disease liability by summarising disease risk across hundreds of
24 thousands of genetic variants. They can be calculated in any genome-wide genotype data-source,
25 using a prediction model based on genome-wide summary statistics from external studies.

26 As genome-wide association studies increase in power, the predictive ability for disease risk will also
27 increase. While PRS are unlikely ever to be fully diagnostic, they may give valuable medical
28 information for risk stratification, prognosis, or treatment response prediction.

29 Public engagement is therefore becoming important on the potential use and acceptability of PRS.
30 However, the current public perception of genetics is that it provides 'Yes/No' answers about the
31 presence/absence of a condition, or the potential for developing a condition, which in not the case for
32 common, complex disorders with of polygenic architecture.

33 Meanwhile, unregulated third-party applications are being developed to satisfy consumer demand for
34 information on the impact of lower risk variants on common diseases that are highly polygenic. Often
35 applications report results from single SNPs and disregard effect size, which is highly inappropriate
36 for common, complex disorders where everybody carries risk variants.

37 Tools are therefore needed to communicate our understanding of genetic predisposition as a
38 continuous trait, where a genetic liability confers risk for disease. Impute.me is one such a tool,
39 whose focus is on education and information on common, complex disorders with polygenetic
40 architecture. Its research-focused open-source website allows users to upload consumer genetics data
41 to obtain PRS, with results reported on a population-level normal distribution. Diseases can only be
42 browsed by ICD10-chapter-location or alphabetically, thus prompting the user to consider genetic
43 risk scores in a medical context of relevance to the individual.

44 Here we present an overview of the implementation of the impute.me site, along with analysis of
45 typical usage-patterns, which may advance public perception of genomic risk and precision medicine.

46

47

1   Introduction

In clinical genetics, testing for rare strong-effect causal variants is routinely performed in the healthcare system to confirm a diagnosis, or to evaluate individual risk suspected from anamnestic information [Baig et al 2016], and in such instances the use of genome sequencing is expanding [Byrjalsen et al 2018]. Meanwhile, outside of the healthcare system, direct to consumer (DTC) genetics expands rapidly providing the public with access individual genetic data profiles and to interpretation of common genetic variants derived from genotyping microarrays. This is developing as a sprawling industry of consumer services with widely diverging standards, including third-party genome analysis services. These services typically provide individual results from analysis of single, common SNPs with (at best) weak effects. They are therefore severely mis-aligned with current state-of-the-art, which at least for common, complex disease is to use polygenic risk scores (PRS) to estimate the combined risk of common variation in the genome [Lewis et al 2017].

We believe that the goal of the academic genetics community should extend beyond theory. This means engaging with the public and assisting those that seek information, even when it means helping them to interpret their own genomic data. We therefore developed impute.me as an online web-app for analysis and education in personal genetic analysis. The web-app is illustrated in figure 1. Using any major DTC vendor, a user can download their raw data and then upload it at impute.me. Uploaded files are checked and formatted according to procedures that have been developed to handle most types of microarray-based consumer genetics data, including an imputation step. This data is then further subjected to automated analysis scripts including polygenic risk score calculations. This includes more than 2000 traits, browsable in different interface-types (modules). Each module is designed with the goal of putting findings in as relevant a context as possible, prompting users to see common variant genetics as a support tool rather than a diagnosis finder. The aim is to provide information as broadly as possible to offer a real alternative to the wide-spread practice of reporting on weak single SNP genotypes for any trait, even though that entails generation of some reports that are below any sensible threshold for clinical usability. We hope that having this as an open and accessible resource for everyone will be of help to the debate on what exactly constitutes clinical usability beyond high-risk pathogenic variants.

In this paper we will describe the i) development and setup, ii) validation and testing and iii) evaluation of usage, and iv) future directions for impute.me. In the section *Development and Setup* we discuss some of the challenges faced when developing a full personal-genome scoring pipeline. The goal of this section is to motivate and explain the choices made in development. In the second section, *Validation and Testing*, we use public biobank data from individuals that are consented for genetic research to test the effect of the impute.me scores on known disease outcomes. The purpose of this section is to test and validate scores, as well as to investigate consequences of some of the challenges that were raised in the first section. In the third section, *Evaluation of Usage*, we evaluate usage-metrics of impute.me users. The goal of this section is to shed light on behaviour patterns of individuals who use DTC genetics for health questions and offer recommendations that may be of use in other personal-genome

80   scoring pipelines. Finally, in the section *Future Directions* we discuss our views on future directions particularly with respect to

81   improving how genetic findings are presented to people.

82

83

2   Development and setup

85   A first challenge in development of personal genomic services is standardization. As the name impute.me implies, all

86   genotype data is processed by imputation of genotype data [Delaneau et al 2013, Howie et al 2009]. This procedure expands the

87   data available into ungenotyped SNPs and increases overlap with public genome-wide association study (GWAS) summary

88   statistics used to estimate risk. It also expands the SNP overlap between microarray types from the major vendors, such as

89   23andme, Myheritage and Ancestry.com. Further, we have found that imputation helps in avoiding major errors, for example

90   strand-flip issues that arise from the dozens of different data formats. Eliminating such problems from further processing is one

91   important step to minimize mis-interpretation of genome analysis. To ensure high standard of reported results, impute.me requires

92   a fully completed imputation for continued analysis.

93   The second challenge is calculation of robust PRS estimates that are accurate, irrespectively of the source of the data.

94   This is particularly important to an application utilized by people from around the world leveraging data from dozens of different

95   vendors and data types. Importantly, PRS calculated from GWAS of a population of (e.g.) European ancestry, will perform better

96   for individuals of the same ancestry, and the systematic shift (i.e. bias) in risk scores in individuals from other populations is a

97   problem [Curtis 2018]. Since studies of all disease-traits are not yet available for all non-European populations, the pragmatic

98   solution has been to include a population-specific normalization attempting to minimize the systematic shifts of scores for non-

99   European ancestry users. Further, it is computationally and logistically easier to implement PRS that use only the most (i.e.

100   genome-wide) significant SNPs (often referred to as top-SNPs), but the prediction strength is better when more SNPs are

101   included (all-SNP) which however, is more sensitive to ethnic biases [Lam et al 2019]. The impute.me pipelines calculate PRS for

102   each trait or disease based on all-SNP based PRS calculations if full genome-wide summary statistics are available and

103   processed, and top-SNP based PRS calculations if not.

104   The third challenge is presentation. For a single rare large-effect variant, such as for the pathogenic variants in the

105   *BRCA* genes conferring very high risk of cancers (odds-ratio >10; Figure 2A, upper left), presentation focuses on absence-vs-

106   presence [Maxwell et al 2016]. However, also low-effect variants, e.g. as in pharmacogenetics, impacting on statin-response, is

107   considered as having potential clinical use [Natarajan et al 2017] (figure 2A, lower right). This difference in effect-magnitude is a

108   major challenge in result presentation, and the line between useful and not depends on context. In the context of a drug-

109   prescription situation or a question of which of two suspected disease risks are the most likely, it may be useful to know such

110   scores. But in the context of an otherwise healthy individual, genetic risks are only relevant if we are very certain of them, they are

111   serious, and preferably actionable (e.g. BRCA variants [Kalia et al 2017]). According to this, that risk-types inherently are not

112   equal, a design choice is that impute.me does not use risk-sorted lists. Currently scores are accessible either through an

113   alphabetically sorted list or in a tree-like setup where genetic scores are reported in a health-context-tree (figure 2B). In this, all

114   scores are included, but scores that are less relevant to healthy individuals (i.e. most of them), are buried deeper into the health-

115   context-tree. As further discussed in the section *Future Challenges*, there are a lot of remaining challenges to solve on this

116   question.

117

118   ## 3   Validation and testing

119   To evaluate pipelines on individuals with known disease outcomes, we investigated 242 samples from the CommonMind

120   data set. The CommonMind data set includes patients with schizophrenia, bipolar disorder and controls, from European ancestry

121   and from African ancestry. For each disorder and each ancestry group the full impute.me pipelines were applied, including

122   imputation and PRS-calculation. Additionally, SNP-sets corresponding to each of three major DTC companies were extracted and

123   re-calculated. This was done to test the hypothesis that PRS calculation in mixed SNP-sets poses particular challenges with

124   regards to missing SNPs. Such sets of genotyped SNPs that are different in each sample, is an unavoidable consequence of

125   working with online data uploads.

126   We found that disease prediction strength, measured as variability explained, corresponded well to theoretical

127   expectations of known SNP heritability [Li et al 2017, Wünnemann et al 2019]. Secondly, we found that using all-SNP scores

128   resulted in better prediction than top-SNP scores, which was as expected [Vilhjálmsson et al 2015]. Thirdly, we found that

129   prediction was more accurate in individuals of European ancestry compared with individuals of African ancestry, which is

130   concordant with the PRS being developed from European Ancestry GWAS [Hou et al 2016, PGC 2014]. These observations

131   match well with findings from studies of PRS in much larger data sets. Estimates of variability explained are probably more

132   precise when derived from larger and more balanced studies, but the intention here is to provide a specific test of impute-me

133   pipelines and address DTC-data related questions.

134   Of importance to this, we found that PRS prediction in mixed samples of non-imputed data causes severe problems.

135   When training PRS algorithms, a SNP set is pre-specified. The pipelines evaluated here were trained with HapMap3 as SNP-set.

136   Similar choices are made in other published PRS. However, such SNP-sets may not match with the SNPs available in

137   downloadable raw data from DTC vendors. We therefore tested what prediction strength would be possible when using raw data

138   directly from DTC vendors, both in a uniform setting (e.g. "all individuals use 23andme v4 data") and in a mixed setting (e.g.

139   "individuals have data from different vendors"). We found that in the uniform setting roughly half the predictive strength remained

140   when using genotype data that is not imputed to match the HapMap3 SNP-sets (figure 3, row 2 and 4). In the mixed setting,

141   virtually no predictive strength remained (figure 3, row 3 and 6). The mixed setting is the reality that is faced, both for third-party

142   analytical services but also for DTC vendors with different chip versions. Imputation is therefore likely to be an essential

143   requirement in such scenarios.

5

144   To compare these findings with approaches that look at one SNP at the time, we extracted the SNPedia/Promethease

145 SNPs that were indicated as associated with schizophrenia [Cariaso et al 2011]. All cases (n=25) and all controls (n=39) had at

146 least one risk-variant from at least one of the 139 SNPs indicated schizophrenia associated. When focusing on SNPs that had

147 the SNPedia/Promethease-defined "*magnitude*"-level (sic.) at > 1.5, we found that 80% of the SCZ cases (20 of 25) had at least

148 one SNPedia/Promethease risk variant. Among the healthy controls 84% (33 of 39) had at least one such risk variant (p=0.9 for

149 difference in proportions). In other words, it is not very predictive to know if you have a schizophrenia SNP. This illustrates the

150 importance of considering more than one SNP at the time.

151   Finally, we compared pipeline reproducibility using two genome-data files, one obtained from MyHeritage and one from

152 Ancestry.com, but sampled from the same person. After processing through the impute-me pipelines the correlation between PRS

153 values over 1468 traits was r=0.933 between the two samples. Traits that showed discrepancy between the two data files typically

154 were based on only few SNPs, of which one did not meet imputation quality thresholds for one of the data files.

155

4 Evaluation of Usage

157   As of June 2019, a total of 28 651 genomes had been uploaded to impute.me, and a total of 3.1 million analytical

158 queries had been performed (figure 4A). The following additional observations about user behaviour may be of use to the genetics

159 research community.

160   Common and well-known diseases are the most sought after. By overall click-count and comparing over several

161 different modules, there is no doubt that users are most interested in common disease types; diseases of the brain, the heart and

162 of the metabolism are more requested. Interface design may of course play important roles in such choices. For example, the

163 choice to serve disease traits as alphabetically sorted lists is likely to artificially inflate interest in e.g. abdominal aneurysm (figure

164 4B). However, the larger interest in psychiatry, cardiovascular and metabolic disorders remain also in the precision medicine

165 module which is not presented as an alphabetically sorted list (figure 4C). It is possible that greater scientific interest in PRS in

166 these fields also drives some of these effects, but we cannot explain why other fields where PRS are actively discussed, such as

167 cancer, are not attracting more attention

168   Likewise, it seems that common disease ("Complex disease module") is more sought after than rare disease ("Rare

169 disease module"); 95% of all users visit the first, whereas only 70% visit the second. Again, interface design and project goals

170 probably play a big role in this – the landing page headers says *Beyond one SNP at the time* and the rare disease module is

171 found in the navigation bar only below seven other module entries. But it may also illustrate a central communication challenge for

172 the field: People are more interested in the genetics of common, complex disease with small effect sizes (figure 2A, lower right),

173 but may interpret the results as if they were for rare disease with large effect sizes (figure 2A, upper left).

174   Finally, we have observed that usage of health genetic data surprisingly often is not just a test-and-forget-event. When

175   plotting query-count as a function of time from first data-access, we find an expected pattern of intense browsing the hours and

176   days after first data access (Figure 4D). However, many users re-visit their data even months and years after first data access,

177   perhaps implying that results are considered and saved and then re-visited at a later time in a different context.

178

5   Future Directions

180   Generation of the PRS data presents one set of challenges but communicating them to people in such a way as to make it both

181   comprehensible and useful presents another [Lipkus et al 1999, Naik et al 2012]. We believe that this is a crucial unmet need in

182   current genetics research, because presenting PRS data in a way that is useful requires an understanding of people's motivations

183   for accessing them in the first place.

184   To date, studies of PRS have focused on providing people with PRS information in relation to specific conditions (e.g. cancer

185   [Bancroft et al 2014, Bancroft et al 2015, Young et al 2017, Smit et al 2018]) for which participants have an indicated risk and

186   exploring understanding and reactions. No studies have examined what motivates people to seek out and access their own PRS

187   for common complex conditions, and little is known about how people understand or respond to the data they receive.

188   PRS information is inherently probabilistic in nature, which is well known to be difficult for people to understand [Hallowell et al

189   1998, Smerecnik et al 2009] and receiving information about genetic risk is not necessarily benign. When people receive genetic

190   test results that they perceive to reflect high risk for a condition, this can have negative impact on outcomes like self-perception

191   and affect, and in the case of receiving high risk test results for Alzheimer's disease – can actually impact objective measures of

192   cognitive performance [Wilhelm et al 2009, Dar-Nimrod et al 2013, Lineweaver et al 2014, Lebowitz et al 2017, Turnwald et al

193   2019]. Therefore, how information about genetic risk is communicated matters.

194   The literature suggests that when communicating risk, the most useful and effective strategy is to use absolute risks [Lipkus et al

195   1999, Naik et al 2012, Reyna et al 2009]. In the case of PRS with modest predictive power, however, this may simply result in re-

196   stating the population prevalence of a disease for everyone [Janssens 2019]. It is therefore important that the predictive strength

197   is also included in this communication; that is how much the genetic component potentially could alter the absolute risk. The

198   genetic component corresponds to the SNP-heritability, and we are therefore exploring how to best include this information (e.g

199   figure 1C). Currently we have registered the SNP-heritability for 294 of the reported traits, available as an experimental option

200   called 'plot heritability'. We believe that a main future direction is to experiment and expand on how to best communicate this to

201   people.

202   It will therefore be useful to have a constant flow of people that are interested in interpreting their genetics and expose them to

203   various modes of presentation. Some could involve statistically advanced concepts, like AUC and SNP-heritability, but others may

204   take simpler approaches, such as the explanatory jar model pioneered for talking with families about genetics [Peay et al 2011,

205   Austin et al 2019]. One may even imagine layered models of increasing complexity. This should be followed-up with

206   questionnaires probing the level of understanding and general impact on users, something that is possible using the impute.me

207   platform.

208

6   Conclusion

210   In summary, impute.me is a fully operational genetic analysis engine covering a very broad range of health-related traits,

211   specifically focusing on optimizing possibilities from microarray-based DNA measurements. The challenges, their solutions, and

212   the curation work behind them are highly relevant today in a setting of highly varying quality in interpretation of personal consumer

213   genetics. They will also continue to be relevant in a future where we can expect both increases in the predictiveness of polygenic

214   risk scores, as well as vast increases in the number of individuals buying consumer genetics. With a directed push towards

215   responsible use of consumer genetics, this may even prove to be an overall clinical benefit.

216   For that reason, the impute.me code is available open-source open-source (see URLs) and the online implementation is

217   free to use, supported by user-donations.

218

219

220

221

7   Methods

7.1   Pre-processing

224   Impute.me users upload raw genotype data from a DTC that is then parked in an imputation queue,

225   which is simply a specific folder on our servers. Submitted jobs are then processed by a cron-job in

226   order of free computing nodes becoming available. This cron-job consists of a series of calls to bash-

227   based programs; first a shapeit call is made to phase the data correctly [Delaneau et al 2013], then an

228   impute2 call is made with 1000 Genomes version 3 as reference [Howie et al 2009, 1000 genomes

229   2015]. Although the pipelines are not guaranteed to handle any format they receive, they currently

230   operate with less than 1% processing failures, meaning uploads that cannot proceed through the full

231   quality control and imputation pipelines. The failures are typically due to file formatting errors,

232   missing chromosomes or any number of other odd data corruptions that real-world data exchange

233   suffers from.

234   Several customizations have been made with the goal of minimizing memory foot print and thereby

235   allowing running in a clustered fashion on a series of small cloud computers. This allows for

236   relatively easy scaling of capacity; one simple setup ("hub-only"), where calculations are run on the

237   same computer as the web-site interface. Another is a hub+node-setup, where a central hub server

238   stores data and shows the web-site, while a scalable number of node-servers perform all

239   computationally heavy calculations. After pre-processing is finished, two new files are created: a .gen

240   file with probabilistic information from imputation calls and a *simple format* file with best guess

241   genotypes, called at a 0.9 impute2 INFO threshold. All further calculations are based on these files.

242

7.2   Polygenic Risk Score Calculation

244   From the pre-processed data a modular set of trait predictor algorithms are applied. For many of the

245   modules, the calculations are trivial. For example, this could be the reporting of presence and/or

246   absence of a specific genotype, such as ACTN3 and ACE-gene SNPs known to be (weakly)

247   associated with athletic performance. These are included mostly because users expect them to be. For

248   other, we rely heavily on PRS.

249   An important distinguishing factor between different PRS algorithms is how risk alleles are selected.

250   A commonly used approach includes variants based on whether they surpass a given p-value

251   threshold in the GWAS, retaining only LD-independent variants using LD-based clumping, often

252   with a p-value threshold of genome-wide significance (p<5e-8). Herein we refer to this approach as

253   the 'top-SNP' approach. The top-SNP approach has the advantage that it is simple to explain, is easy

254   to obtain for many GWAS, and has a light computational burden, e.g. [Buniello et al 2019, Watanabe

255   et al 2019]. However, research has repeatedly shown that the inclusion of variants that do not achieve

256   genome-wide significance improves the variance explained by PRS, with PRS including all variants

257   often explaining the most variance. PRS based on GWAS effect sizes that have undergone shrinkage

258   to account for the LD between variants have been shown to explain more variance than PRS which

259   account for LD via LD-based clumping [Vilhjálmsson et al 2015]. Herein we refer to this approach as

260   the all-SNP approach. It is more computationally and practically intensive to implement at scale.

261   Consequently, within Impute.me each trait or disease reported shows all-SNP based PRS calculations

262   if such is available, and top-SNP based PRS calculations if not.

263   In the top-SNP calculation mode, the results are scaled such that the mean of a population is zero and

264   the standard deviation (SD) is 1, according to the relevant 1000 Genomes super-population; either

265   African, Ad Mixed American, East Asian, European or South Asian.

266    $\text{Population-score}_{snp} = \text{frequency}_{snp} * 2 * \text{beta}_{snp}$

267   Zero-centered-score = Σ Beta$_{snp}$ * Effect-allele-count$_{snp}$ - Population-score$_{snp}$

268   Z-score = Zero-centered-score / Standard-deviation$_{population}$

269   Where beta (or log(odds ratio)) is the reported effect size for the SNP effect allele, frequency$_{SNP}$ is the

270   allele frequency for the effect allele, and the Effect-allele-count$_{SNP}$ is the allele count from genotype

271   data (0, 1, or 2).

272   In the all-SNP calculation, the scaling is similar, but done empirically, i.e. based on previous

273   Impute.me users of matching ethnicity. This mode of scaling is also available as an optional

274   functionality in the top-SNP calculations, and generally seems to match well with the default 1000

275   genomes super population scaling.

276   The all-SNP scores were derived using weightings from the LDpred algorithm [Vilhjálmsson et al

277   2015]. This algorithm adjusts the effect of each SNP allele for those of other SNP alleles in linkage

278   disequilibrium (LD) with it, and also takes into account the likelihood of a given allele to have a true

279   effect according to a user-defined parameter, which here was taken as *wt1* i.e. the full set of SNPs.

280   The algorithm was directed to use hapmap3 SNPs that had a minor allele frequency >0.05, Hardy-

281   Weinberg equilibrium P>1e-05 and genotype-yield >0.95, consistent with our expectation that these

282   would be the best imputed SNPs after full pipeline processing.

283   **7.3   Pipeline Testing**

284   The CommonMind genotypes measured with the microarray of the type H1M were downloaded

285   along with phenotypic information. Each sample was processed through the impute.me pipelines,

286   using the batch-upload functionality. Reported ethnicity was compared with pipeline (genotype)

287   assigned ethnicity and found to be concordant.

288 After pipeline completion, we extracted three PRS for each sample, corresponding to SCZ all-SNP,

289 SCZ top-SNP and BP all-SNP. In the github-repository for impute.me, these three corresponds to the

290 scores labelled *SCZ_2014_PGC_EXCL_DK.EurUnrel.hapmap3.all.ldpred.effects*,

291 *schizophrenia_25056061*, *BIP_2016_PGC.All.hapmap3.all.ldpred.effects* trait-IDs [PGC 2014, Hou

292 et al 2016]. These extracted scores formed the basis of the row #1 and #4 calculations in figure 3. The

293 remaining rows were created by subsetting the best guess imputed genotypes into new sets of users,

294 corresponding to each of three major DTC vendors and then re-running the scoring algorithms either

295 with uniform data or mixed data. Uniform data is here defined as all samples 195 samples having the

296 same set of SNPs available, corresponding to one of three DTC vendors in each run. Mixed data is

297 defined as samples having different sets of SNPs available, a set corresponding to actual distributions

298 of customers from different DTC vendors, with distributions re-drawn 100 times. We estimated the

299 predictive ability of the PRS using Nagelkerke's R^2 and AUC.

300 **7.4 Usage evaluation**

301 A log data freeze was performed 2019-06-08, by making a copy of all usage log files and then

302 removing the uniqueID of each user. This was done to prevent it from being linked with the genetic

303 data of that user. The exception was the publicly available permanent test user with ID

304 id_613z86871, which was lifted out before analysis and is not included in other summary statistics.

305 Generally, a user corresponds to an uploaded genome with a unique md5sum. Click-through rates

306 were calculated as fraction of users that performed any query in the module in question, e.g. the

307 precision medicine module was only launched in September 2018 and therefore only counts clicks

308 from people who have used it. Plots were generated using base-R version 3.4.2 and cytoscape version

309 3.71.

310

12

Impute.me: DTC based polygenic scores.

311 **8   Figures**

312

313 **Fig 1 – basic pipeline setup from the user point of view.** On upload of a genome, data is checked according QC parameters

314 that have been developed to handle most types of microarray-based consumer genetics data. The genome is then imputed using

315 1000 Genomes as reference (**left**). The imputed data is then further subjected to automated analysis scripts from 15 different

316 modules, most of which are based on polygenic risk score calculations. The calculations include 1859 traits from GWAS studies,

317 634 traits from the UK Biobank, as well as customized modules for height, and drug response. Most polygenic risk scores use

318 GWAS significant SNPs out of necessity, although 20 major diseases are based on LDpred all-SNP scores (**center**). User can

319 then browse their scores in relation to the population, shown together with a chart displaying how much varability is explained

320 (**right**).

321

13

322

Fig.2 Theoretical background of the analysis pipeline A) Clinical genetics currently concern high-effect DNA-variants that often can only be sequenced (*red*). Additionally, high-effect variants such as APOE4 and a small subset of BRCA1 and BRCA2 pathogenic variants are possible to measure using microarray (*blue*, includes several other variants not shown in plot, e.g. Parkinson's variants). There may be an untapped potential for valuable clinical information in polygenic risk scores (PRS) for common disease (*green*), for example for type 2 diabetes (T2D), coronary artery disease (CAD) or Statin response [Natarajan et al 2017, Wünnemann et al 2019, Khera et al 2018]. It is a primary aim of the impute.me project to make this potential available more broadly, balancing the practice of relying on individual GWAS SNPs and/or reporting of single SNP genotypes (*pink*). **B)** The secondary aim is to provide genetic scores in a relevant context, exemplified in the precision medicine module showing the so-called health-context tree. This tree consists of all entries from the international classification of disease (ICD-10), linked to all genetic studies. It allows browsing of polygenic risk scores in a relevant context. In the example shown, the tree is open on the psychiatry chapter, showing polygenic risk scores for schizophrenia (F20), unipolar depression (F32) and bipolar depression (F31). While these scores have little predictive relevance for a healthy individual, they may be useful in the context of psychiatric evaluation, particularly in the case of more extreme scores.

336

Impute.me: DTC based polygenic scores.

#	Matching SNP-set	Uniform missingness	Matching Ancestry	Variability explained (%)			Example
1	+	+	+	13.06	5.88	7.75	SNP-set matching the PRS *(e.g. imputed data)*
2		+	+	4.4±2.3	3.0±2	6.2±0.9	Wrong SNP-set, uniform missingness *(e.g. one non-imputed microarray type with a general PRS)*
3			+	0.01±3.9	0.03±1.6	0.0042±2.9	As #2, but with non-uniform set of microarrays *(e.g. live online setting with mixed format uploads)*
4	+	+		5.52	0.0001	2.24	As #1, but for individuals with African ancestry
5		+		2.5±0.7	0.16±0.17	5±2.4	As #2, but for individuals with African ancestry
6				0.029±3.2	0.001±0.82	0.079±1.0	As #3, but for individuals with African ancestry

337

Fig 3. **Pipeline evaluation using publicly available genotyped cohorts.** Three scores were calculated in individuals of European ancestry and relevant diagnoses ($n_{control}$=39, n_{SCZ}=25 and n_{BP} = 39): a schizophrenia (SCZ) all-SNP score (n_{SNP}= 558406), a SCZ top-SNP score (n_{SNP}=93) and a bipolar (BP) all-SNP score (n_{SNP}= 554977). The BP top-SNP score only used 5 genome-wide significant SNPs and was not tested. The proportion of variance explained (Nagelkerke R^2) is shown above each case-control pair. **B)** Testing different conditions of ancestry and input SNP-sets. Row #1 corresponds to the variability explained after processing through the full impute.me pipeline, i.e the same calculation shown in the plot. Row #2 shows the prediction level when the PRS algorithm uses input samples from only one type of direct-to-consumer (DTC) vendor, but the algorithm has not been trained specifically for that SNP-set. Values are given as mean±SD of three analyses in which SNP-sets were all from either 23andme (v4), ancestry-com, or myheritage, respectively. Row #3 shows the prediction when each sample uses different SNP-sets, i.e. the actual situation when dealing with user-uploaded DTC data online. Values are given as mean±SD over hundred random drawings of combinations of the 23andme (v4), ancestrycom, and myheritage sets, in proportions of 55%, 30%, 15%, respectively. These proportions correspond to what is observed in live users. Rows #4-6 shows the same as #1-3 but calculated for CommonMind individuals of African ancestry ($n_{control}$=47, n_{SCZ}=39 and n_{BP} = 6). The corresponding AUC values for this figure is 0.693, 0.614, 0.634 for row #1. For row #2: 0.55±0.12, 0.53±0.084, 0.62±0.012 and for row #3 0.58±0.047, 0.55±0.03,

352   0.57±0.047. Additionally, an extended version of the figure is available at www.impute.me/prsExplainer where additional metrics

353   of prediction can be explored interactively.

354

Impute.me: DTC based polygenic scores.

A)

B)

C)

D)

355

356   Fig 4. **Detailed usage statistics**. **A)** Overall count of unique users and unique analysis requests since august 2015. Each *request*

357   corresponds to a specific analysis, e.g. the risk score for a disease, or a view in the ICD-10 based map in the precision medicine

358   module. Each *user* corresponds to an uploaded genome with a unique md5sum. There is no check for twins, altered files or users

359   with data from separate DTC companies. **B)** Distribution of user-interests in a trait in the *complex disease module.* In this module,

17

360   each disease-entry is presented on an alphabetically sorted list, with aortic aneurysm being the default value. The percentage

361   indicates how many of the users that scrolled down and selected this disease at least once (n_{clicks} = 871855). **C)** Distribution of

362   interests in a trait in the *precision medicine module.* In this module, each disease-entry is presented in the layout of the ICD-10

363   classification system. The click through-rate reflects how many users pursued information in a given chapter or sub-chapter, as

364   percentage of total amount of clicks (n_{clicks} = 114039). **D)** Analysis of how individuals use the interface over time. For each user,

365   the number of queries is shown as a function of time after they first access their data. Since all data is automatically deleted after

366   two years, no queries extend beyond 730 days. The colour code indicates the submission date. The highlighted black line

367   indicates the publically available permanent test user with ID id_613z86871, which is omitted from all other analyses.

368

369

9   Conflict of Interest

371   The voluntary donations received by impute.me go to a registered company, from where all of it is
372   used to pay for server-costs. The company is a Danish-law IVS company with ID 37918806,
373   financially audited under Danish tax law.

10   Author Contributions

375   LF coded the code. All authors contributed to interpretation, drafting the work, critical revision for
376   important intellectual content, as well as final approval of the manuscript.

11   Funding

12   Acknowledgments

13   Manuscript contributions to the field (200 words required)

391

392   The manuscript describes an approach for obtaining polygenic risk scores (PRS) for any individual
393   using direct-to-consumer genetics. PRS are considered state-of-the-art for genetic prediction in

394 common, complex diseases, and the availability of such methods therefore have the potential expand
395 the usage of genetics beyond rare mendelian disorders. At the same time, the usage and interpretation
396 of direct-to-consumer genetics is by many considered a controversial issue that needs more
397 regulatory oversight. By setting this type of information free in the form of open-source code and
398 web-applications, this manuscript provides input to a debate on what constitutes beneficial use of
399 genetics in common, common complex disease.

400

14 Data Availability Statement

402 Publicly available datasets were analyzed in this study. This data can be found here: CommonMind
403 data DOI: 10.7303/syn2759792.

15 URLs

405 Code repository: https://github.com/lassefolkersen/impute-me

406 Web ressource: https://www.impute.me/

407

16 References

409 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis
410 GR. A global reference for human genetic variation. Nature. 2015 Oct 1;526(7571):68-74. doi: 10.1038/nature15393. PubMed PMID: 26432245;
411 PubMed Central PMCID: PMC4750478.

412 Austin JC. Evidence-Based Genetic Counseling for Psychiatric Disorders: A Road Map. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a036608. doi:
413 10.1101/cshperspect.a036608. [Epub ahead of print] PubMed PMID: 31501264.

414 Baig SS, Strong M, Rosser E, Taverner NV, Glew R, Miedzybrodzka Z, Clarke A, Craufurd D; UK Huntington's Disease Prediction Consortium, Quarrell
415 OW. 22 Years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium. Eur J Hum Genet. 2016
416 Oct;24(10):1396-402. doi: 10.1038/ejhg.2016.36. Epub 2016 May 11. Erratum in: Eur J Hum Genet. 2016 Oct;24(10):1515. Eur J Hum Genet. 2017
417 Nov;25(11):1290. PubMed PMID: 27165004; PubMed Central PMCID: PMC5027682.

418 Bancroft EK, Castro E, Ardern-Jones A, Moynihan C, Page E, Taylor N, Eeles RA, Rowley E, Cox K. "It's all very well reading the letters in the genome,
419 but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer. Fam
420 Cancer. 2014 Dec;13(4):625-35. doi: 10.1007/s10689-014-9734-3. PubMed PMID: 24980079.

421 Bancroft EK, Castro E, Bancroft GA, Ardern-Jones A, Moynihan C, Page E, Taylor N, Eeles RA, Rowley E, Cox K. The psychological impact of undergoing
422 genetic-risk profiling in men with a family history of prostate cancer. Psychooncology. 2015 Nov;24(11):1492-9. doi: 10.1002/pon.3814. Epub 2015
423 Apr 14. PubMed PMID: 25872100.

424 Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A, Morales J, Mountjoy E, Sollis E, Suveges D, Vrousgou O,
425 Whetzel PL, Amode R, Guillen JA, Riat HS, Trevanion SJ, Hall P, Junkins H, Flicek P, Burdett T, Hindorff LA, Cunningham F, Parkinson H. The NHGRI-EBI
426 GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019 Jan
427 8;47(D1):D1005-D1012. doi: 10.1093/nar/gky1120. PubMed PMID: 30445434; PubMed Central PMCID: PMC6323933.

428 Byrjalsen A, Stoltze U, Wadt K, Hjalgrim LL, Gerdes AM, Schmiegelow K, Wahlberg A. Pediatric cancer families' participation in whole-genome
429 sequencing research in Denmark: Parent perspectives. Eur J Cancer Care (Engl). 2018 Nov;27(6):e12877. doi: 10.1111/ecc.12877. Epub 2018 Jul 17.
430 PubMed PMID: 30016002.

431 Cariaso M, Lennon G. SNPedia: a wiki supporting personal genome annotation, interpretation and analysis. Nucleic Acids Res. 2012 Jan;40(Database
432 issue):D1308-12. doi: 10.1093/nar/gkr798. Epub 2011 Dec 2. PubMed PMID: 22140107; PubMed Central PMCID: PMC3245045.

433 Curtis D. Polygenic risk score for schizophrenia is more strongly associated with ancestry than with schizophrenia. Psychiatr Genet. 2018 Oct;28(5):85-
434 89. doi: 10.1097/YPG.0000000000000206. PubMed PMID: 30160659.

Impute.me: DTC based polygenic scores.

435 Dar-Nimrod I, Zuckerman M, Duberstein PR. The effects of learning about one's own genetic susceptibility to alcoholism: a randomized experiment.
436 Genet Med. 2013 Feb;15(2):132-8. doi: 10.1038/gim.2012.111. Epub 2012 Aug 30. Erratum in: Genet Med. 2013 May;15(5):412. PubMed PMID:
437 22935722.

438 Delaneau O, Howie B, Cox AJ, Zagury JF, Marchini J. Haplotype estimation using sequencing reads. Am J Hum Genet. 2013 Oct 3;93(4):687-96. doi:
439 10.1016/j.ajhg.2013.09.002. PubMed PMID: 24094745; PubMed Central PMCID: PMC3791270.

440 Hallowell N, Statham H, Murton F. Women's Understanding of Their Risk of Developing Breast/Ovarian Cancer Before and After Genetic Counseling. J
441 Genet Couns. 1998 Aug;7(4):345-64. doi: 10.1023/A:1022072017436. PubMed PMID: 26141523.

442 Hou L, Bergen SE, Akula N, Song J, Hultman CM, Landén M, Adli M, Alda M, Ardau R, Arias B, Aubry JM, Backlund L, Badner JA, Barrett TB, Bauer M,
443 Baune BT, Bellivier F, Benabarre A, Bengesser S, Berrettini WH, Bhattacharjee AK, Biernacka JM, Birner A, Bloss CS, Brichant-Petitjean C, Bui ET,
444 Byerley W, Cervantes P, Chillotti C, Cichon S, Colom F, Coryell W, Craig DW, Cruceanu C, Czerski PM, Davis T, Dayer A, Degenhardt F, Del Zompo M,
445 DePaulo JR, Edenberg HJ, Étain B, Falkai P, Foroud T, Forstner AJ, Frisén L, Frye MA, Fullerton JM, Gard S, Garnham JS, Gershon ES, Goes FS,
446 Greenwood TA, Grigoroiu-Serbanescu M, Hauser J, Heilbronner U, Heilmann-Heimbach S, Herms S, Hipolito M, Hitturlingappa S, Hoffmann P,
447 Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kelsoe JR, Kittel-Schneider S, Kliwicki S, Koller DL, König B, Lackner N, Laje G, Lang M, Lavebratt C,
448 Lawson WB, Leboyer M, Leckband SG, Liu C, Maaser A, Mahon PB, Maier W, Maj M, Manchia M, Martinsson L, McCarthy MJ, McElroy SL, McInnis
449 MG, McKinney R, Mitchell PB, Mitjans M, Mondimore FM, Monteleone P, Mühleisen TW, Nievergelt CM, Nöthen MM, Novák T, Nurnberger JI Jr,
450 Nwulia EA, Ösby U, Pfennig A, Potash JB, Propping P, Reif A, Reininghaus E, Rice J, Rietschel M, Rouleau GA, Rybakowski JK, Schalling M, Scheftner WA,
451 Schofield PR, Schork NJ, Schulze TG, Schumacher J, Schweizer BW, Severino G, Shekhtman T, Shilling PD, Simhandl C, Slaney CM, Smith EN, Squassina
452 A, Stamm T, Stopkova P, Streit F, Strohmaier J, Szelinger S, Tighe SK, Tortorella A, Turecki G, Vieta E, Volkert J, Witt SH, Wright A, Zandi PP, Zhang P,
453 Zollner S, McMahon FJ. Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Hum Mol
454 Genet. 2016 Aug 1;25(15):3383-3394. doi: 10.1093/hmg/ddw181. Epub 2016 Jun 21. PubMed PMID: 27329760; PubMed Central PMCID:
455 PMC5179929.

456 Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies.
457 PLoS Genet. 2009 Jun;5(6):e1000529. doi: 10.1371/journal.pgen.1000529. Epub 2009 Jun 19. PubMed PMID: 19543373; PubMed Central PMCID:
458 PMC2689936.

459 Janssens ACJW. Proprietary Algorithms for Polygenic Risk: Protecting Scientific Innovation or Hiding the Lack of It? Genes (Basel). 2019 Jun 13;10(6).
460 pii: E448. doi: 10.3390/genes10060448. PubMed PMID: 31200546; PubMed Central PMCID: PMC6627729.

461 Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, Herman GE, Hufnagel SB, Klein TE, Korf BR, McKelvey KD, Ormond KE, Richards CS, Vlangos
462 CN, Watson M, Martin CL, Miller DT. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update
463 (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017 Feb;19(2):249-255. doi:
464 10.1038/gim.2016.190. Epub 2016 Nov 17. Erratum in: Genet Med. 2017 Apr;19(4):484. PubMed PMID: 27854360.

465 Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, Kathiresan S. Genome-wide polygenic
466 scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018 Sep;50(9):1219-1224. doi:
467 10.1038/s41588-018-0183-z. Epub 2018 Aug 13. PubMed PMID: 30104762; PubMed Central PMCID: PMC6128408.

468 Lam M, Chen CY, Li Z, Martin AR, Bryois J, Ma X, Gaspar H, Ikeda M, Benyamin B, Brown BC, Liu R, Zhou W, Guan L, Kamatani Y, Kim SW, Kubo M,
469 Kusumawardhani AAAA, Liu CM, Ma H, Periyasamy S, Takahashi A, Xu Z, Yu H, Zhu F; Schizophrenia Working Group of the Psychiatric Genomics
470 Consortium; Indonesia Schizophrenia Consortium; Genetic REsearch on schizophreniA neTwork-China and the Netherlands (GREAT-CN), Chen WJ,
471 Faraone S, Glatt SJ, He L, Hyman SE, Hwu HG, McCarroll SA, Neale BM, Sklar P, Wildenauer DB, Yu X, Zhang D, Mowry BJ, Lee J, Holmans P, Xu S,
472 Sullivan PF, Ripke S, O'Donovan MC, Daly MJ, Qin S, Sham P, Iwata N, Hong KS, Schwab SG, Yue W, Tsuang M, Liu J, Ma X, Kahn RS, Shi Y, Huang H.
473 Comparative genetic architectures of schizophrenia in East Asian and European populations. Nat Genet. 2019 Nov 18. doi: 10.1038/s41588-019-0512-
474 x. [Epub ahead of print] PubMed PMID: 31740837.

475 Lebowitz MS, Ahn WK. Testing positive for a genetic predisposition to depression magnifies retrospective memory for depressive symptoms. J Consult
476 Clin Psychol. 2017 Nov;85(11):1052-1063. doi: 10.1037/ccp0000254. PubMed PMID: 29083221; PubMed Central PMCID: PMC5679424.

477 Lewis CM, Vassos E. Prospects for using risk scores in polygenic medicine. Genome Med. 2017 Nov 13;9(1):96. doi: 10.1186/s13073-017-0489-y.
478 PubMed PMID: 29132412; PubMed Central PMCID: PMC5683372.

479 Li Z, Chen J, Yu H, He L, Xu Y, Zhang D, Yi Q, Li C, Li X, Shen J, Song Z, Ji W, Wang M, Zhou J, Chen B, Liu Y, Wang J, Wang P, Yang P, Wang Q, Feng G, Liu
480 B, Sun W, Li B, He G, Li W, Wan C, Xu Q, Li W, Wen Z, Liu K, Huang F, Ji J, Ripke S, Yue W, Sullivan PF, O'Donovan MC, Shi Y. Genome-wide association
481 analysis identifies 30 new susceptibility loci for schizophrenia. Nat Genet. 2017 Nov;49(11):1576-1583. doi: 10.1038/ng.3973. Epub 2017 Oct 9.
482 PubMed PMID: 28991256.

483 Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy
484 older adults. Am J Psychiatry. 2014 Feb;171(2):201-8. doi: 10.1176/appi.ajp.2013.12121590. PubMed PMID: 24170170; PubMed Central PMCID:
485 PMC4037144.

486 Lipkus IM, Hollands JG. The visual communication of risk. J Natl Cancer Inst Monogr. 1999;(25):149-63. Review. PubMed PMID: 10854471.

487 Maxwell KN, Domchek SM, Nathanson KL, Robson ME. Population Frequency of Germline BRCA1/2 Mutations. J Clin Oncol. 2016 Dec;34(34):4183-
488 4185. Epub 2016 Oct 31. PubMed PMID: 27551127.

489 Naik G, Ahmed H, Edwards AG. Communicating risk to patients and the public. Br J Gen Pract. 2012 Apr;62(597):213-6. doi: 10.3399/bjgp12X636236.
490 PubMed PMID: 22520906; PubMed Central PMCID: PMC3310025.

491 Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, Sartori S, Fuster V, Reilly DF, Butterworth A, Rader DJ, Ford I, Sattar N,
492 Kathiresan S. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the
493 Primary Prevention Setting. Circulation. 2017 May 30;135(22):2091-2101. doi: 10.1161/CIRCULATIONAHA.116.024436. Epub 2017 Feb 21. PubMed
494 PMID: 28223407; PubMed Central PMCID: PMC5484076.

495 Peay HL, Austin J. How to Talk with Families About Genetics and Psychiatric Illness. Book. W. W. Norton & Company; 1 edition (January 17, 2011)

496 Reyna VF, Nelson WL, Han PK, Dieckmann NF. How numeracy influences risk comprehension and medical decision making. Psychol Bull. 2009
497 Nov;135(6):943-73. doi: 10.1037/a0017327. Review. PubMed PMID: 19883143; PubMed Central PMCID: PMC2844786.

498 Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature.
499 2014 Jul 24;511(7510):421-7. doi: 10.1038/nature13595. Epub 2014 Jul 22. PubMed PMID: 25056061; PubMed Central PMCID: PMC4112379.

500 Smerecnik CM, Mesters I, Verweij E, de Vries NK, de Vries H. A systematic review of the impact of genetic counseling on risk perception accuracy. J
501 Genet Couns. 2009 Jun;18(3):217-28. doi: 10.1007/s10897-008-9210-z. Epub 2009 Mar 17. Review. PubMed PMID: 19291376.

502 Smit AK, Newson AJ, Best M, Badcock CA, Butow PN, Kirk J, Dunlop K, Fenton G, Cust AE. Distress, uncertainty, and positive experiences associated
503 with receiving information on personal genomic risk of melanoma. Eur J Hum Genet. 2018 Aug;26(8):1094-1100. doi: 10.1038/s41431-018-0145-z.
504 Epub 2018 Apr 30. PubMed PMID: 29706632; PubMed Central PMCID: PMC6057946.

505 Turnwald BP, Goyer JP, Boles DZ, Silder A, Delp SL, Crum AJ. Learning one's genetic risk changes physiology independent of actual genetic risk. Nat
506 Hum Behav. 2019 Jan;3(1):48-56. doi: 10.1038/s41562-018-0483-4. Epub 2018 Dec 10. PubMed PMID: 30932047; PubMed Central PMCID:
507 PMC6874306.

508 Vilhjálmsson BJ, Yang J, Finucane HK, Gusev A, Lindström S, Ripke S, Genovese G, Loh PR, Bhatia G, Do R, Hayeck T, Won HH; Schizophrenia Working
509 Group of the Psychiatric Genomics Consortium, Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) study, Kathiresan S, Pato M,
510 Pato C, Tamimi R, Stahl E, Zaitlen N, Pasaniuc B, Belbin G, Kenny EE, Schierup MH, De Jager P, Patsopoulos NA, McCarroll S, Daly M, Purcell S,
511 Chasman D, Neale B, Goddard M, Visscher PM, Kraft P, Patterson N, Price AL. Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk
512 Scores. Am J Hum Genet. 2015 Oct 1;97(4):576-92. doi: 10.1016/j.ajhg.2015.09.001. PubMed PMID: 26430803; PubMed Central PMCID: PMC4596916.

513 Watanabe K, Stringer S, Frei O, Umićević Mirkov M, de Leeuw C, Polderman TJC, van der Sluis S, Andreassen OA, Neale BM, Posthuma D. A global
514 overview of pleiotropy and genetic architecture in complex traits. Nat Genet. 2019 Sep;51(9):1339-1348. doi: 10.1038/s41588-019-0481-0. Epub 2019
515 Aug 19. PubMed PMID: 31427789.

516 Wilhelm K, Meiser B, Mitchell PB, Finch AW, Siegel JE, Parker G, Schofield PR. Issues concerning feedback about genetic testing and risk of depression.
517 Br J Psychiatry. 2009 May;194(5):404-10. doi: 10.1192/bjp.bp.107.047514. PubMed PMID: 19407269.

518 Wünnemann F, Sin Lo K, Langford-Avelar A, Busseuil D, Dubé MP, Tardif JC, Lettre G. Validation of Genome-Wide Polygenic Risk Scores for Coronary
519 Artery Disease in French Canadians. Circ Genom Precis Med. 2019 Jun;12(6):e002481. doi: 10.1161/CIRCGEN.119.002481. Epub 2019 Jun 11. PubMed
520 PMID: 31184202; PubMed Central PMCID: PMC6587223.

521 Young MA, Forrest LE, Rasmussen VM, James P, Mitchell G, Sawyer SD, Reeve K, Hallowell N. Making Sense of SNPs: Women's Understanding and
522 Experiences of Receiving a Personalized Profile of Their Breast Cancer Risks. J Genet Couns. 2018 Jun;27(3):702-708. doi: 10.1007/s10897-017-0162-z.
523 Epub 2017 Nov 22. PubMed PMID: 29168041.